Products
SIRT4 antibody
- Product Name
- SIRT4 antibody
- Catalogue No.
- FNab07882
- Size
- 100μg
- Form
- liquid
- Purification
- Immunogen affinity purified
- Purity
- ≥95% as determined by SDS-PAGE
- Clonality
- polyclonal
- Isotype
- IgG
- Storage
- PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
Immunogen
- Immunogen
- sirtuin(silent mating type information regulation 2 homolog) 4
- Alternative Names
- Sir2l4 antibody
- UniProt ID
- Q9Y6E7
- Observed MW
- 35 kDa
Application
- Tested Applications
- ELISA, WB, IHC
- Recommended dilution
- WB: 1:500-1:2000; IHC: 1:20-1:200
Validated Images
PC-3 cells were subjected to SDS PAGE followed by western blot with FNab07882(SIRT4 Antibody) at dilution of 1:300
Immunohistochemistry of paraffin-embedded human skeletal muscle tissue slide using FNab07882(SIRT4 Antibody) at dilution of 1:50
- Background
- Acts as NAD-dependent protein lipoamidase, ADP-ribosyl transferase and deacetylase(PubMed:19220062). Catalyzes more efficiently removal of lipoyl-and biotinyl-than acetyl-lysine modifications. Inhibits the pyruvate dehydrogenase complex(PDH) activity via the enzymatic hydrolysis of the lipoamide cofactor from the E2 component, DLAT, in a phosphorylation-independent manner(PubMed:25525879). Catalyzes the transfer of ADP-ribosyl groups onto target proteins, including mitochondrial GLUD1, inhibiting GLUD1 enzyme activity. Acts as a negative regulator of mitochondrial glutamine metabolism by mediating mono ADP-ribosylation of GLUD1: expressed in response to DNA damage and negatively regulates anaplerosis by inhibiting GLUD1, leading to block metabolism of glutamine into tricarboxylic acid cycle and promoting cell cycle arrest(PubMed:16959573). In response to mTORC1 signal, SIRT4 expression is repressed, promoting anaplerosis and cell proliferation(PubMed:23663782). Acts as a tumor suppressor(PubMed:23562301, PubMed:23663782). Also acts as a NAD-dependent protein deacetylase: mediates deacetylation of 'Lys-471' of MLYCD, inhibiting its activity, thereby acting as a regulator of lipid homeostasis(PubMed:23746352). Controls fatty acid oxidation by inhibiting PPARA transcriptional activation. Impairs SIRT1:PPARA interaction probably through the regulation of NAD(+) levels(PubMed:24043310, PubMed:20685656). Down-regulates insulin secretion(By similarity).
